A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

A new weight loss treatment that can be taken as either a daily pill or a weekly injection has shown very promising results ...

This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s competition ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...